Status:
COMPLETED
The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Fatty Liver
Liver Dysfunction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The role of Helicobacter pylori(HP)in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is controversial.
Detailed Description
This randomized double blind clinical trial was performed in dyspeptic patients with positive antibody to HP and the evidence of fatty liver in ultrasonography. After excluding other causes, participa...
Eligibility Criteria
Inclusion
- dyspeptic patients with positive antibody to H.pylori and
- persistent elevated aminotransferase levels with the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic.
Exclusion
- alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),
- heart disease (ischemic or congestive),
- hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion),
- renal disease (serum creatinine concentration of \> 1.5 mg/dl),
- any severe systemic co-morbidities, neoplasm,
- using any hepatotoxic medication during the past 3 months,
- previous history of peptic ulcer,
- previous history of H.pylori eradication,
- existence of alarm signs (weight loss, dysphagia, anemia, vomiting, positive family history of gastrointestinal cancers), and
- pregnant or lactating women.
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01876108
Start Date
July 1 2012
End Date
July 1 2013
Last Update
July 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology clinic, Sina Hospital
Tehran, Tehran Province, Iran